Feed APM
AP

Aptorum Group Limited

APM · NASDAQ

$8.26 -12.13% (-$1.14)
Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Weak
2/9
Valuation
-
N/A
EV/EBITDA N/A
P/S N/A
P/B N/A
Growth
-
N/A
Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A
Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
-
N/A
ROE N/A
ROA N/A
Asset turnover N/A
Debt
-
N/A
Current ratio N/A
Int. coverage N/A
Net debt/EBITDA N/A
Stability
0 /100
Unstable
Beta 0.17x
EPS volatility N/A
Profitable years N/A

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o APM
Online

O podjetju

Aptorum Group Limited (APM) is a global biotechnology company focused on the development of new drug candidates for the treatment of various diseases. Their research targets the treatment of infectious diseases, neurological and gastrointestinal disorders, oncological diseases, and other serious health conditions. Aptorum Group focuses on innovative therapeutic approaches, including the use of AI and bioinformatics technologies to discover new drug targets and therapies. The company is also active in the development of herbal-based medicines and traditional healing practices. Their aim is to bring innovative and effective therapeutic approaches to improve the health of patients worldwide. Aptorum Group Limited (APM) shares could be suitable for investors seeking investments in biotechnology companies with potential for innovative therapeutic development and global growth.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Ian Huen

Employees

2

Headquarters

Princeton

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.